Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jovan Perunicic

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cardiology|June 14, 2011
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
International Journal of Cardiology|May 26, 2012
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 23, 2013
Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Thrombosis and Thrombolysis|September 11, 2007
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndromeJovan Perunicic, Nebojsa M Antonijevic, Predrag Miljic, et al.
International Journal of Cardiology|July 12, 2005
Significance of recurrences of new atrial fibrillation in acute myocardial infarctionMilika Asanin, Jovan Perunicic, Igor Mrdovic, et al.
Coronary Artery Disease|November 24, 2011
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Interventional Cardiology|February 5, 2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical ApplicationRatko Lasica, Milika Asanin, Lazar Djukanovic, et al.
Journal of Clinical Apheresis|August 26, 2006
Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudinNebojsa M Antonijevic, Nebojsa B Savic, Jovan Perunicic, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Cardiology|June 14, 2011
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
International Journal of Cardiology|May 26, 2012
Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 23, 2013
Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding scoreIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Thrombosis and Thrombolysis|September 11, 2007
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndromeJovan Perunicic, Nebojsa M Antonijevic, Predrag Miljic, et al.
International Journal of Cardiology|July 12, 2005
Significance of recurrences of new atrial fibrillation in acute myocardial infarctionMilika Asanin, Jovan Perunicic, Igor Mrdovic, et al.
Coronary Artery Disease|November 24, 2011
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Interventional Cardiology|February 5, 2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical ApplicationRatko Lasica, Milika Asanin, Lazar Djukanovic, et al.
Journal of Clinical Apheresis|August 26, 2006
Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudinNebojsa M Antonijevic, Nebojsa B Savic, Jovan Perunicic, et al.
Pageof 2